RAF Gene Mutation clinical trials at UCSF

1 research study open to eligible people

A RAF gene mutation is a change in a gene that affects cell growth control. UCSF is leading early phase studies of oral medicines in RAF-mutant solid tumors. These studies document safety, dosing plans, and how the drug is absorbed.

Showing trials for

  • NST-628 Oral Tablets in Subjects With Solid Tumors

    open to eligible people ages 18 years and up

    This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

    San Francisco, California and other locations

Last updated: